Carl Zeiss Meditec (ETR:AFX) Trading Down 0.5% - Time to Sell?

Key Points

• Shares down 0.5% to €24.32 on Monday (intraday low €23.80) with 221,957 shares traded — a 135% increase vs. average volume, indicating unusually high trading activity.
• The stock is trading below its 50-day (€26.73) and 200-day (€37.26) moving averages, signaling short- and long-term weakness; valuation metrics include a market cap of $2.27 billion, P/E 13.0, PEG 2.83 and beta 1.41.
• Carl Zeiss Meditec is a German medical-technology company focused on ophthalmology and microsurgery, providing diagnostic and treatment devices for cataracts, glaucoma, retinal disorders and related digital products.

Carl Zeiss Meditec AG (ETR:AFX - )'s share price traded down 0.5% during trading on Monday . The company traded as low as €23.80 and last traded at €24.32. 221,957 shares traded hands during mid-day trading, an increase of 135% from the average session volume of 94,405 shares. The stock had previously closed at €24.45.

Carl Zeiss Meditec Stock Performance

The stock has a 50 day moving average price of €26.73 and a two-hundred day moving average price of €37.26. The company has a debt-to-equity ratio of 28.70, a current ratio of 2.35 and a quick ratio of 2.47. The company has a market capitalization of $2.27 billion, a price-to-earnings ratio of 13.00, a price-to-earnings-growth ratio of 2.83 and a beta of 1.41.

Carl Zeiss Meditec Company Profile

Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, North America, and Asia. It operates in two segments, Ophthalmology and Microsurgery. The Ophthalmology segment offers products and solutions for the diagnosis and treatment of chronic eye diseases, such as ametropia (refraction), cataracts, glaucoma, and renital disorders. This segment also provides devices for general ophthalmological examination and care, including slit lamps, refractometers, tonometers, optical coherence tomography devices, and fundus cameras; and devices for functional diagnostics (perimeters), as well as digital products for storage, evaluation, and sharing of clinical data.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.